Shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) reached a new 52-week high on Thursday . The company traded as high as $57.83 and last traded at $57.26, with a volume of 130300 shares traded. The stock had previously closed at $56.26.
A number of research firms have recently weighed in on ENTA. TheStreet raised Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Wednesday, December 13th. Zacks Investment Research lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. JMP Securities upped their price objective on Enanta Pharmaceuticals from $40.00 to $53.00 in a research report on Wednesday, October 4th. Finally, Royal Bank of Canada reissued a “buy” rating and issued a $54.00 target price on shares of Enanta Pharmaceuticals in a report on Friday, October 20th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Enanta Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $46.25.
The company has a market cap of $1,110.27, a P/E ratio of 65.97 and a beta of 0.64.
A number of large investors have recently made changes to their positions in the stock. GAM Holding AG purchased a new position in Enanta Pharmaceuticals in the second quarter valued at about $108,000. Municipal Employees Retirement System of Michigan increased its holdings in Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 110 shares in the last quarter. SG Americas Securities LLC increased its holdings in Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 237 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in Enanta Pharmaceuticals by 62.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,702 shares in the last quarter. Finally, Aperio Group LLC purchased a new position in shares of Enanta Pharmaceuticals during the 2nd quarter worth approximately $206,000. Hedge funds and other institutional investors own 66.83% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Enanta Pharmaceuticals (ENTA) Sets New 12-Month High at $57.83” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/23/enanta-pharmaceuticals-enta-sets-new-12-month-high-at-57-83.html.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.